



## UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 02 2004

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/699,362	10/31/2003	Ivan Svendsen	6600.200-US

Reza Green, Esq.  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540

CONFIRMATION NO. 3030

## FORMALITIES LETTER



\*OC000000013514681\*

Date Mailed: 08/12/2004

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at

11/03/2004 MAHME1 00000012 141447 10699362

01 FC:1051 130.00 DA

patin21help@uspto.gov or patin3help@uspto.gov

**SUMMARY OF FEES DUE:**

Total additional fee(s) required for this application is \$130 for a Large Entity

- \$130 Late oath or declaration Surcharge.

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

*Y.G.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Attorney Docket No.: 6600.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Svendsen et al.

Serial No.: 10/699,362

Group Art Unit: To be assigned

Filed: October 31, 2003

Examiner: To be assigned

For: Humanized Tissue Factor Antibodies

**RESPONSE TO NOTICE TO FILE MISSING PARTS  
AND TO NOTICE TO COMPLY WITH SEQUENCE RULES**

Mail Stop: Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

In response to the Notice to Comply with Sequence Rules dated August 12, 2004, Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "Humanized Tissue Factor Antibodies Seq" and of the accompanying identically labeled diskette is the same. Furthermore, the information contained in the attached "Humanized Tissue Factor Antibodies Seq" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

In Addition, please charge the required fee, estimated to be \$130.00, to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447 in order to comply with the Notice to File Missing Parts. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Len S. Smith, Reg. No. 43,139

Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Date: October 28, 2004

**Use the following customer number for all correspondence regarding this application.**

**23650**

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6600.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Svendsen et al.

Serial No.: 10/699,362

Group Art Unit: To be assigned

Filed: October 31, 2003

Examiner: To be assigned

For: Humanized Tissue Factor Antibodies

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Response to Notice to File Missing Parts and Comply with Sequence Rules(in duplicate)
2. Petition and Fee for Extension of Time (in duplicate)
3. Copy of Notice to File Missing Parts and Comply with Sequence Rules
4. Executed Combined Declaration and Power of Attorney
5. Certified copy of Priority Application
6. Sequence Listing
7. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on **October 28, 2004**

Csaba Attila Szokolczai  
(name of person mailing paper)

  
(signature of person mailing paper)